EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients

Thornthun Ueaphongsukkit, Suwasin Udomkarnjananun iD, Jakapat Vanichanan, Kamonwan Jutivorakool, Natavudh Townamchai, Salin Wattanatorn, Phalin Kamolwat, Sasiwimol Ubolyam, Stephen J Kerr, Anchalee Avihingsanon, Pajaree Chariyavilaskul iD, Yingyos Avihingsanon

Journal of Antimicrobial Chemotherapy · 2026

DOI: 10.1093/jac/dkaf439 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Thornthun Ueaphongsukkit und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Rifampin, Renal Dialysis, Latent Tuberculosis, Antitubercular Agents. Die Arbeit nennt 19 Literaturangaben. Gefördert von: Ratchadapisek Sompoch Endowment Fund of Chulalongkorn University, Second Century Fund, Chulalongkorn University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A one-month regimen of daily isoniazid plus rifapentine (1HP) is endorsed by WHO for latent tuberculosis infection (LTBI), showing efficacy and safety in people with human immunodeficiency virus (HIV). However, the pharmacokinetics (PK) of rifapentine in end-stage renal disease (ESRD) patients on dialysis remain unknown.

Methods

We conducted a 24-hour multiple-dose PK study of daily rifapentine in 11 dialysis-dependent patients with LTBI. Participants received rifapentine 450–600 mg plus isoniazid 300 mg daily for 4 weeks. Plasma samples were collected on day 14 at eight time points: pre-dose and 1, 2, 4, 6, 8, 12 and 24 hours post-dose. Rifapentine concentrations were measured using validated HPLC. PK parameters were compared with historical cohort from non-dialysed populations.

Results

Participants (63% male, mean age 49) received a mean rifapentine dose of 9.9 ± 1.6 mg/kg. Eleven (69%) completed treatment; five discontinued due to adverse events or transplantation. Median maximum concentration (Cmax) was 11.4 µg/mL (IQR, 8.7–13.7); median AUC0–24 was 177 µg·h/mL (IQR, 134–206).

Conclusions

Rifapentine exposure in dialysis patients was lower than in non-dialysed historical cohorts, highlighting the need for larger studies to refine dosing in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinRenal DialysisLatent TuberculosisAntitubercular AgentsHumansMaleFemaleMiddle AgedAdultIsoniazidKidney Failure, ChronicAgedPlasma

Substanzen

rifapentineRifampinIsoniazidAntitubercular Agents

Autor:innen und Institutionen

  • Department of Medicine, Division of Infectious Diseases, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Department of Medicine, Division of Nephrology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Department of Medicine, Center of Excellence in Renal Immunology and Renal Transplantation, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Excellence Center for Organ Transplantation, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
  • Department of Disease Control, Tuberculosis Division, Ministry of Public Health, Nonthaburi, Thailand.
  • HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.

ORCID-Profile: Suwasin Udomkarnjananun, Pajaree Chariyavilaskul

Förderung

  • Ratchadapisek Sompoch Endowment Fund of Chulalongkorn University
  • Second Century Fund
  • Chulalongkorn University

Zitieren

APA

Ueaphongsukkit, T., Udomkarnjananun, S., Vanichanan, J., Jutivorakool, K., Townamchai, N., Wattanatorn, S., Kamolwat, P., Ubolyam, S., Kerr, S. J., Avihingsanon, A., Chariyavilaskul, P., & Avihingsanon, Y. (2026). Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf439

Vancouver

Ueaphongsukkit T, Udomkarnjananun S, Vanichanan J, Jutivorakool K, Townamchai N, Wattanatorn S, et al. Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkaf439

BibTeX
@article{Ueaphongsukkit2026,
  author = {Ueaphongsukkit, Thornthun and Udomkarnjananun, Suwasin and Vanichanan, Jakapat and Jutivorakool, Kamonwan and Townamchai, Natavudh and Wattanatorn, Salin and Kamolwat, Phalin and Ubolyam, Sasiwimol and Kerr, Stephen J and Avihingsanon, Anchalee and Chariyavilaskul, Pajaree and Avihingsanon, Yingyos},
  title = {Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  doi = {10.1093/jac/dkaf439}
}
Kostenlos starten →